Novavax (NVAX) Earnings Analysis

Novavax (NVAX) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it beat with EPS 0.11 USD vs -0.66 USD est (+116.7%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -14.65.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NVAX next report earnings?

No confirmed upcoming earnings date is currently scheduled for NVAX. This page updates as the calendar is published.

NVAX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-260.11 USD-0.66 USD+116.7%Beat
2025-05-082.93 USD0.71 USD+312.7%Beat
2025-02-27-0.51 USD-0.75 USD+32%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

NVAX valuation and analyst view

Trailing P/E-14.65
Trailing EPS-0.53795 USD
Price / book-8.92
Dividend yield0.00%
Market cap1.31B
Analyst consensusBuy (17 buy / 3 hold / 3 sell)
Avg price target14.5 USD

Related research pages

Frequently asked questions

When is Novavax (NVAX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for NVAX. This page updates as the calendar is published.

Did NVAX beat earnings last quarter?

In its 2026-02-26 report, NVAX posted EPS of 0.11 USD versus a -0.66 USD estimate — a beat of 116.7%.

What is NVAX's earnings track record?

Over the last 3 reported quarters with consensus data, NVAX beat estimates 3 times (100%).

What is NVAX's current P/E ratio and EPS?

NVAX trades at a trailing P/E of -14.65 on trailing EPS of -0.5379541390038952 USD.

What do analysts rate NVAX?

Analyst consensus is "Buy" across 23 ratings (0 strong buy, 17 buy, 3 hold, 3 sell, 0 strong sell). Average 12-month price target: 14.5 USD.